China type 2 diabetes treatment status survey of treatment pattern of oral drugs users

Journal of Diabetes

Volumn 7, Issue 2, 2015, Pages 166-173

  Ji, Linong ^a   Lu, Juming ^b   Weng, Jianping ^c   Jia, Weiping ^d   Tian, Haoming ^e   Zhu, Dalong ^f   Xing, Xiaoping ^g   Guo, Lixin ^h  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^d Shanghai 6th Hospital   (China)

^e SICHUAN UNIVERSITY   (China)

^f THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

^g PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^h BEIJING HOSPITAL   (China)

Author keywords

Oral drugs; Treatment; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CEREBROVASCULAR ACCIDENT; CHINA; COMBINATION CHEMOTHERAPY; COMORBIDITY; DIABETES MELLITUS; DIABETIC FOOT; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DYSLIPIDEMIA; EDEMA; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEDICAL RECORD REVIEW; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; OUTPATIENT; PRIORITY JOURNAL; TREATMENT DURATION; CLINICAL TRIAL; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; PROGNOSIS; RETROSPECTIVE STUDY;

ADMINISTRATION, ORAL; CHINA; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 84924180563     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12165     Document Type: Article

References (20)

1. Yang W, Lu J, Weng J etal. Prevalence of diabetes among men and women in China. N Engl J Med. 2010; 362: 1090-1101.
2. Pan C, Shang S, Kirch W, Thoenes M. Burden of diabetes in the adult Chinese population: A systematic literature review and future projections. Int J Gen Med. 2010; 3: 173-179.
3. Alcorn T, Ouyang Y. Diabetes saps health and wealth from China's rise. Lancet. 2012; 379: 2227-2228.
4. Yang W, Zhao W, Xiao J etal. Medical care and payment for diabetes in China: Enormous threat and great opportunity. PLoS One. 2012; 7: e39513.
5. Zhang SL, Chen ZC, Yan L, Chen LH, Cheng H, Ji LN. Determinants for inadequate glycaemic control in Chinese patients with mild-to-moderate type 2 diabetes on oral antidiabetic drugs alone. Chin Med J (Engl). 2011; 124: 2461-2468.
6. Yang W, Juming L, Linong L etal. China guideline for type 2 diabetes. China J Diab. 2012; 20: S1-S37.
7. Krentz AJ, Bailey CJ. Oral antidiabetic agents: Current role in type 2 diabetes mellitus. Drugs. 2005; 65: 385-411.
8. Dornhorst A. Insulinotropic meglitinide analogues. Lancet. 2001; 358: 1709-1716.
9. Carroll MF, Izard A, Riboni K, Burge MR, Schade DS. Control of postprandial hyperglycemia: Optimal use of short-acting insulin secretagogues. Diabetes Care. 2002; 25: 2147-2152.
10. Carroll MF, Gutierrez A, Castro M, Tsewang D, Schade DS. Targeting postprandial hyperglycemia: A comparative study of insulinotropic agents in type 2 diabetes. J Clin Endocrinol Metab. 2003; 88: 5248-5254.
11. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: A nested case-control analysis. Diabetes Care. 2008; 31: 2086-2091.
12. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-853.
13. Bron M, Marynchenko M, Yang H, Yu AP, Wu EQ. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs. Postgrad Med. 2012; 124: 124-132.
14. Gitt AK, Bramlage P, Binz C etal. Hypoglycaemia is more frequent in type 2 diabetic patients with co-morbid vascular disease: An analysis of the DiaRegis registry 1. Eur J Prev Cardiol. 2012; 19: 765-772.
15. Tschope D, Bramlage P, Binz C, Krekler M, Deeg E, Gitt AK. Incidence and predictors of hypoglycaemia in type 2 diabetes - An analysis of the prospective DiaRegis registry 1. BMC Endocr Disord. 2012; 12: 23.
16. Pan C, Yang W, Jia W, Weng J, Tian H. Management of Chinese patients with type 2 diabetes, 1998-2006: The Diabcare-China surveys. Curr Med Res Opin. 2009; 25: 39-45.
17. Liu Z, Fu C, Wang W, Xu B. Prevalence of chronic complications of type 2 diabetes mellitus in outpatients - A cross-sectional hospital based survey in urban China. Health Qual Life Outcomes. 2010; 8: 62.
18. Del Prato S, Penno G, Miccoli R. Changing the treatment paradigm for type 2 diabetes. Diabetes Care. 2009; 32 (Suppl. 2): S217-222.
19. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006; 29: 2638-2643.
20. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012; 35: 1473-1478.